2015 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/09/15Verastem Reports Third Quarter 2015 Financial and Corporate Results
BOSTON--(BUSINESS WIRE)--Nov. 9, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the third quarter ended September 30, 2015, and also provided an overview of certain corporate developments. “Our mission is to improve survival and the quality of life for patients battling cancer through the combination of our c... 
Printer Friendly Version
11/04/15Verastem to Present Preclinical Data at SITC 2015
BOSTON--(BUSINESS WIRE)--Nov. 4, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting & Associated Programs being held November 4-8, in National Harbor, Maryland. The details of the presentations at SITC are as follows: ... 
Printer Friendly Version
10/27/15Verastem to Present Preclinical Data at the 2015 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
BOSTON--(BUSINESS WIRE)--Oct. 27, 2015-- Verastem, Inc. (NASDAQ:VSTM) today announced four poster presentations at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held November 5-9, 2015 in Boston, Massachusetts. The details for the poster presentations at AACR-NCI-EORTC are as follows: Title: FAK/PYK2 Inhibitors Defactinib and VS-4718 Enhance Immune Checkpoint Inhibitor Ef... 
Printer Friendly Version
10/08/15Verastem Announces Reduction of Workforce
BOSTON--(BUSINESS WIRE)--Oct. 8, 2015-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced a reduction of its workforce by approximately 50% to 20 full time employees. “This is an extremely painful decision that will impact many of our passionate and talented colleagues, and their families,” said Robert Forrester, President and Chief Execu... 
Printer Friendly Version
09/28/15Verastem Stops Enrollment Due to Futility in the COMMAND Study of VS-6063 for the Treatment of Malignant Pleural Mesothelioma
— No difference in VS-6063 versus placebo in either the intent to treat population or patients with Merlin-low tumors — — Company to Host Conference Call Today at 8:30 AM ET — BOSTON--(BUSINESS WIRE)--Sep. 28, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the Company has stopped enrollment in the Phase 2 registr... 
Printer Friendly Version
09/24/15Verastem Announces New Research Published in the Journal Cell That Highlights the Potential of FAK Inhibition to Enhance the Efficacy of Anti-Tumor Immunotherapy
BOSTON--(BUSINESS WIRE)--Sep. 24, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that researchers from the University of Edinburgh have published a study in the journal Cell which highlights the potential of FAK inhibition to enable the body’s immune system to fight cancer. The paper discusses results from preclinical research sh... 
Printer Friendly Version
09/17/15Verastem to Present Preclinical Data at ESMO/ECCO 2015
BOSTON--(BUSINESS WIRE)--Sep. 17, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced poster presentations at the 40th European Society for Medical Oncology (ESMO)/18th European Cancer Congress being held September 25-29, 2015 at the Messe Wien Exhibition & Congress Centre in Vienna, Austria. ... 
Printer Friendly Version
09/10/15Verastem Presents Clinical and Preclinical Data at the 16th World Conference on Lung Cancer
BOSTON--(BUSINESS WIRE)--Sep. 10, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced oral and poster presentations at the 16th World Conference on Lung Cancer (WCLC) which took place September 6 - 9, 2015, in Denver, CO. Four oral presentations included results from a Phase 2 clinical trial of VS-6063 (defactinib) in advanced refract... 
Printer Friendly Version
09/03/15Verastem to Present at Rodman and Renshaw 17th Annual Global Investment Conference
BOSTON--(BUSINESS WIRE)--Sep. 3, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the Rodman and Renshaw 17th Annual Global Investment Conference on Thursday, September 10 at 3:50 p.m. ET at the St. Regis Hotel in New York City. A live webcast of the presentation will be available on the company's w... 
Printer Friendly Version
08/26/15Verastem Issues Statement Regarding WCLC Presentations
BOSTON--(BUSINESS WIRE)--Aug. 26, 2015-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today issued the following statement in response to inquiries regarding the anticipated oral presentation of VS-6063 (defactinib) data from a Phase 2 study in patients with KRAS mutant non-small cell lung cancer (NSCLC) at the 16th World Conference on Lung Cancer (WCLC): ... 
Printer Friendly Version
08/26/15Verastem to Present Data at the 16th World Conference on Lung Cancer
BOSTON--(BUSINESS WIRE)--Aug. 26, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced oral and poster data presentations at the 16th World Conference on Lung Cancer (WCLC) being held September 6-9, 2015 at the Colorado Convention Center in Denver, CO. The details for the data presentations at WCLC are as follows: Oral Presentations ... 
Printer Friendly Version
08/10/15Verastem Reports Second Quarter 2015 Financial and Corporate Results
— COMMAND Interim Analysis Anticipated in Third Quarter 2015 — BOSTON--(BUSINESS WIRE)--Aug. 10, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the second quarter ended June 30, 2015, and also provided an overview of certain corporate accomplishments and plans. “Execution of the ongoing COMMAND trial cont... 
Printer Friendly Version
07/02/15Verastem to Present at Cantor Fitzgerald’s Inaugural Health Care Conference
BOSTON, Mass.--(BUSINESS WIRE)--Jul. 2, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the Cantor Fitzgerald Inaugural Health Care Conference on Wednesday, July 8 at 2:00 p.m. ET at Le Parker Meridien Hotel in New York City. A live webcast of the presentation will be available on the company's web... 
Printer Friendly Version
06/17/15Verastem to Present at 2015 JMP Securities Life Sciences Conference
BOSTON--(BUSINESS WIRE)--Jun. 17, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the 2015 JMP Securities Life Sciences Conference on Tuesday, June 23 at 9:00 a.m. ET at The St. Regis New York in New York City. A live webcast of the presentation will be available on the company's website at http://... 
Printer Friendly Version
06/10/15Verastem Announces Executive Management Changes
Dr. Joanna Horobin to Transition from Chief Medical Officer to the Role of Senior Advisor; Lou Vaickus, MD, FACP, Named Interim Chief Medical Officer BOSTON--(BUSINESS WIRE)--Jun. 10, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that Joanna Horobin, M.B., Ch.B., Chief Medical Officer (CMO), will transition to the role of Se... 
Printer Friendly Version
05/27/15Verastem to Present at Jefferies 2015 Healthcare Conference
BOSTON--(BUSINESS WIRE)--May 27, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the Jefferies 2015 Healthcare Conference on Wednesday, June 3 at 10:30 a.m. ET at the Grand Hyatt New York in New York City. A live webcast of the presentation will be available on the company's website at http://phx.c... 
Printer Friendly Version
05/19/15Verastem Announces Analyst Event and Webcast at the 2015 ASCO Annual Meeting
- Guest Speakers to Give Presentations on Mesothelioma and Rationale for Targeting Cancer Stem Cells through FAK Inhibition - BOSTON--(BUSINESS WIRE)--May 19, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will host an analyst and investor event on Sunday, May 31st at the 2015 American Society of Clinical Oncology (A... 
Printer Friendly Version
05/12/15Verastem to Present at 2015 UBS Global Health Care Conference
BOSTON--(BUSINESS WIRE)--May 12, 2015-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the 2015 UBS Global Healthcare Conference on Tuesday, May 19 at 1:30 p.m. ET at the Sheraton New York Times Square Hotel in New York City. A live webcast of the presentation will be available on the company's website ... 
Printer Friendly Version
05/11/15Verastem Reports First Quarter 2015 Financial and Corporate Results
— COMMAND Interim Analysis Anticipated in Third Quarter 2015 — BOSTON--(BUSINESS WIRE)--May 11, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the first quarter ended March 31, 2015, and also provided an overview of certain corporate accomplishments and plans. “The team continues to efficiently execute on... 
Printer Friendly Version
04/30/15Verastem to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Apr. 30, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will participate at the following upcoming investor conferences: Deutsche Bank 40th Annual Healthcare Conference on Wednesday, May 6, 2015 at 3:30 p.m. ET at the InterContinental Hotel in Boston Mizuho S... 
Printer Friendly Version
04/22/15Verastem Presents Encouraging Scientific Data on the Preferential Targeting of Cancer Stem Cells at the 2015 American Association of Cancer Research Annual Meeting
BOSTON--(BUSINESS WIRE)--Apr. 22, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the presentation of scientific data at the 2015 American Association of Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia, PA. “The scientific research presented by both Verastem and our... 
Printer Friendly Version
03/19/15Verastem to Present Data at the 2015 American Association of Cancer Research Annual Meeting
BOSTON--(BUSINESS WIRE)--Mar. 19, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced data presentations at the 2015 American Association of Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia, PA. The details for the data presentations at AACR are as follows: ... 
Printer Friendly Version
03/10/15Verastem Reports Year-End 2014 Financial Results
— COMMAND Interim Analysis Expected Second Quarter 2015 — BOSTON--(BUSINESS WIRE)--Mar. 10, 2015-- Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today reported financial results for the year ended December 31, 2014, and also commented on corporate accomplishments and plans. "COMMAND enrollment remains on track and we continue to anticipate condu... 
Printer Friendly Version
03/03/15Verastem to Present at 27th Annual ROTH Conference
BOSTON--(BUSINESS WIRE)--Mar. 3, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the 27th Annual ROTH Conference on Monday, March 9 at 3:30 p.m. PT at the Ritz-Carlton in Dana Point, CA. A live webcast of the presentation will be available on the company's website at www.verastem.com. An arc... 
Printer Friendly Version
02/12/15Verastem Receives Orphan Drug Designation from FDA for VS-5584 in Mesothelioma
BOSTON--(BUSINESS WIRE)--Feb. 12, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that VS-5584 has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of mesothelioma. The designation was created to encourage the development of drugs that may provide significant benefit to patients suffering from ... 
Printer Friendly Version
02/05/15Verastem Announces the Grant of Inducement Awards
BOSTON--(BUSINESS WIRE)--Feb. 5, 2015-- Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that on February 2, 2015, the Company granted stock options to seven new employees to purchase an aggregate of 210,000 shares of common stock. The stock options were granted as inducements material to the new employees entering into employment with Verastem pursuant to N... 
Printer Friendly Version
02/03/15Verastem to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Feb. 3, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the company will present at the following upcoming investor conferences: 17th Annual BIO CEO & Investor Conference on Tuesday, February 10 at 1:30 p.m. ET at the Waldorf Astoria Hotel in New York City Le... 
Printer Friendly Version
01/29/15Verastem Announces Closing of $54 Million Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
BOSTON--(BUSINESS WIRE)--Jan. 29, 2015-- Verastem, Inc., (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the closing of the previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,087,500 shares of common stock, at the public offering price of $6.50 per share. The exercise o... 
Printer Friendly Version
01/22/15Verastem Announces Pricing of Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Jan. 22, 2015-- Verastem, Inc., (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the pricing of its previously announced underwritten public offering of 7,250,000 shares of its common stock, offered at a price of $6.50 per share to the public. The net proceeds to Verastem from this offering are expected to be approximately $44.1 million, after... 
Printer Friendly Version
01/20/15Verastem Announces Proposed Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--Jan. 20, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it intends to offer and sell $40 million of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size... 
Printer Friendly Version
01/20/15Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma
BOSTON--(BUSINESS WIRE)--Jan. 20, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that VS-5584 has received orphan medicinal product designation from the European Commission for use in mesothelioma. The designation was created to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases. ... 
Printer Friendly Version
01/20/15Verastem Doses First Patient in Phase 1 Clinical Trial Evaluating VS-5584 in Combination with VS-6063 in Mesothelioma
-Study Builds Upon Encouraging Clinical Progress for Both VS-6063 and VS-5584- -Synergistic Activity of VS-6063 and VS-5584 Demonstrated in Preclinical Models of Mesothelioma- BOSTON--(BUSINESS WIRE)--Jan. 20, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced dosing of the first patient in a new clinical trial evaluating ... 
Printer Friendly Version
01/16/15Verastem Announces Publication of Scientific Data for VS-5584 in Cancer Research
BOSTON--(BUSINESS WIRE)--Jan. 16, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that a paper, titled “PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells,” has been published in Cancer Research, a peer-reviewed journal of the American Association for Cancer Research (AACR). The paper discusses results from ... 
Printer Friendly Version
01/08/15Verastem Provides Year-End 2014 Update and Outlook for 2015
-COMMAND Study Currently On Track for Completion of Enrollment by Year-End 2015- -Signals of Clinical Activity in all Programs Targeting Cancer Stem Cells Have Been Observed- -Management to Host Conference Call Today at 4:30 PM ET- -(877) 341-5660 (U.S. and Canada) or (315) 625-3226 (international). Passcode: 60568979. To access the live slide presentation: http://bit.ly/1vYH8yN- BOSTON--(BUSINESS WIRE)--Jan. 8,... 
Printer Friendly Version
01/05/15Verastem to Host Conference Call and Slide Webcast on Thursday, January 8 at 4:30pm ET
-Management to Provide 2014 Year-End Update and 2015 Outlook- BOSTON--(BUSINESS WIRE)--Jan. 5, 2015-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that the Company will host a conference call and slide webcast on Thursday, January 8, 2015 at 4:30 p.m. Eastern Time to review the company’s progress in 2014 and discuss upcoming milestones for 2015.... 
Printer Friendly Version